{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:45:26Z","timestamp":1770511526801,"version":"3.49.0"},"reference-count":213,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicinal Research Reviews"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content>, first discovered as the oncogene responsible for <jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>eline <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>onough <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>arcoma, is a type III receptor tyrosine kinase that binds to the macrophage or monocyte colony\u2010stimulating factor (<jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>\u20101). Signal transduction through that binding results in survival, proliferation, and differentiation of monocyte\/macrophage lineage. Overexpression of <jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>\u20101 and\/or <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> has been implicated in a number of disease states such as the growth of metastasis of certain types of cancer, in promoting osteoclast proliferation in bone osteolysis, and many inflammatory disorders. Inhibition of <jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>\u20101 and\/or <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> may help treat these pathological conditions. This article reviews <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> gene, <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> kinase, <jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>\u20101, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201034, and their roles in bone osteolysis, cancer biology, and inflammation. Monoclonal antibodies, <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> crystal structure, and small molecule <jats:styled-content style=\"fixed-case\">FMS<\/jats:styled-content> kinase inhibitors of different chemical scaffolds are also reviewed.<\/jats:p>","DOI":"10.1002\/med.21258","type":"journal-article","created":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T06:17:13Z","timestamp":1332397033000},"page":"599-636","source":"Crossref","is-referenced-by-count":32,"title":["<scp>FMS<\/scp> Kinase Inhibitors: Current Status and Future Prospects"],"prefix":"10.1002","volume":"33","author":[{"given":"Mohammed I.","family":"El\u2010Gamal","sequence":"first","affiliation":[{"name":"Biomedical Research Institute Korea Institute of Science and Technology P.O. Box 131 Cheongryang Seoul 130\u2010650 Republic of Korea"},{"name":"Department of Biomolecular Science University of Science and Technology 113 Gwahangno Yuseong\u2010gu, Daejeon 305\u2010333 Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan S.","family":"Anbar","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute Korea Institute of Science and Technology P.O. Box 131 Cheongryang Seoul 130\u2010650 Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Ho","family":"Yoo","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute Korea Institute of Science and Technology P.O. Box 131 Cheongryang Seoul 130\u2010650 Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang\u2010Hyun","family":"Oh","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute Korea Institute of Science and Technology P.O. Box 131 Cheongryang Seoul 130\u2010650 Republic of Korea"},{"name":"Department of Biomolecular Science University of Science and Technology 113 Gwahangno Yuseong\u2010gu, Daejeon 305\u2010333 Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203957"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/35077225"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9083"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2155"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2106"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1579"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.5.12.3458"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-419X(88)90011-X"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1154370"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg804"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0171-2985(96)80016-7"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1064-2722(08)60060-2"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.3.1399"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0807762105"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2004.09.016"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.68.1.144"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar318"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood.V82.5.1422.1422","article-title":"Long\u2010term follow\u2010up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony\u2010stimulating factor","volume":"82","author":"Nemunaitis J","year":"1993","journal-title":"Blood"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.09.050"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-12-5"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.69.1.373"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1385\/CBB:34:1:001"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO;2-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.12.018"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737199"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117761"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20055"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000173903.26886.20"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/heart.90.1.25"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1811"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2940"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208655"},{"key":"e_1_2_11_34_1","first-page":"31","article-title":"Expression of fms gene product in breast cancer cells","volume":"10","author":"Haga T","year":"2001","journal-title":"Nyugan Kiso Kenkyu"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01031-10"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.5.2264"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1194637"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10102"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.111"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.01.037"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5484.1504"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.21.2.115"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.2741\/1102"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3562"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.11.072"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116179"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.5.1733"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.136.2.7835314"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650050716"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.49.34967"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(96)00013-0"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.060834"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26132"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:CLIN.0000006873.65590.68"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502000102"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.01.059"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm801406h"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.356"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.85"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1027"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4005"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.11.9.1219"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1256"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.4.2011"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1177\/153537020422900101"},{"key":"e_1_2_11_66_1","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/blood.V77.8.1796.1796","article-title":"Increased circulating colony\u2010stimulating factor\u20101 in patients with preleukemia, leukemia, and lymphoid malignancies","volume":"77","author":"Janowska\u2010Wieczorek A","year":"1991","journal-title":"Blood"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.6070"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.222537099"},{"key":"e_1_2_11_69_1","first-page":"4379","article-title":"The constitutive production of colony stimulating factor 1 by invasive human breast cancer cells","volume":"20","author":"Yee LD","year":"2000","journal-title":"Anticancer Res"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.6.727"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0699-3"},{"key":"e_1_2_11_72_1","first-page":"285","article-title":"Expression of CSF\u20101 and its receptor CSF\u20101R in non\u2010hematopoietic neoplasms","volume":"107","author":"Kascinski B","year":"2002","journal-title":"Cancer Treat Res"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1278"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5804"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0961"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3523"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081605"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.08.017"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.12.032"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-0774.2007.00042.x"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1823"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.07.093"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.991"},{"key":"e_1_2_11_84_1","first-page":"697","article-title":"Proliferation, macrophage colony\u2010stimulating factor, and macrophage colony\u2010stimulating factor\u2010receptor expression of alveolar macrophages in active sarcoidosis","volume":"62","author":"Kreipe H","year":"1990","journal-title":"Lab Invest"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.8.1638"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00068.x"},{"key":"e_1_2_11_87_1","first-page":"291","article-title":"Macrophage colony\u2010stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans","volume":"140","author":"Rosenfeld ME","year":"1992","journal-title":"Am J Pathol"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1272\/jnms1923.62.260"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel356"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23667"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.7.613"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202332999"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2356"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029751"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0171-2985(00)80048-0"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/31.10.653"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/0925-4439(93)90153-R"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91653-4"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.129429"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076117"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-007-6147-x"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.7.4744"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.10.7367"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119891"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.07.018"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.01.015"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00453.2007"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8672"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.13.1740"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.72.3.530"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960103)65:1<112::AID-IJC19>3.0.CO;2-I"},{"key":"e_1_2_11_112_1","first-page":"314","article-title":"Paradoxical stimulation of normal and leukemic rat hematopoiesis by monoclonal antibody to CSF\u20101 receptor","volume":"24","author":"Shadduck RK","year":"1996","journal-title":"Exp Hematol"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2009.02.023"},{"key":"e_1_2_11_114_1","unstructured":"CarrollJA DasTK AllanCM NemaS ZengDL.Human anti\u2010humanM\u2010CSFantibody in the presence of chelating agent surfactant buffer and tonicity agent for treating neoplasm and inflammation. WO 2006\/096461 [Int Pat Appl 2006]."},{"key":"e_1_2_11_115_1","unstructured":"KavanaughM LiuC.Anti\u2010(M\u2010CSF) antibodies and osteoclast inhibitors for preventing and treating osteolytic disorders and bone loss associated with cancer metastasis. WO 2007\/081879 [Int Pat Appl 2007]."},{"key":"e_1_2_11_116_1","unstructured":"Dose\u2010escalating multiple dose study ofPD\u20100360324 in combination with methotrexate in patients with rheumatoid arthritis.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00550355(Retrieved October 18 2011)."},{"key":"e_1_2_11_117_1","unstructured":"A phaseI\/II open\u2010label study ofMCS110 in patients with prostate cancer and bone metastases.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00757757(Retrieved October 18 2011)."},{"key":"e_1_2_11_118_1","unstructured":"BedianV DevalarajaM N LowJE MobleyJL KellermannS\u2010A FoltzI Haak\u2010FrendschoM.Human anti\u2010MCSFantibodies for diagnosis and treatment of inflammation neurological disease atherogenesis cardiac disease and cancer. GB 2405873; WO 2005\/030124 [UK Patent Appl 2005; Int Pat Appl 2005]."},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.03.029"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0107023"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1399-3"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2011.58"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-266296"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M608183200"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/prot.10259"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403319200"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00505-7"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.2741\/hubbard"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-220467"},{"key":"e_1_2_11_130_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.11.9.4698"},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.17.6738"},{"key":"e_1_2_11_132_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.40.24476"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05181.x"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb06211.x"},{"key":"e_1_2_11_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2007.01.036"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2010.01.056"},{"key":"e_1_2_11_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.01.078"},{"key":"e_1_2_11_138_1","unstructured":"http:\/\/www.rcsb.org\/pdb."},{"key":"e_1_2_11_139_1","unstructured":"IlligC BallentineS ChenJ MeegallaS RudolphM WallM WilsonK DesjarlaisR MolloyC MantheyC FloresC.Imidazolecarboxamides and related compounds as inhibitors of c\u2010fms kinase and their preparation pharmaceutical compositions and use for treatment of various inflammations cancers and cardiovascular diseases. WO 2006047277 A2 [PCT Int Appl 2006]."},{"key":"e_1_2_11_140_1","unstructured":"PlayerMR BaindurN BrandtB ChadhaN PatchRJ AsgariD GeorgiadisT.Preparation ofN\u2010substituted imidazolecarboxamides as c\u2010fms kinase inhibitors. US Pat Appl Publ 2006 US 20060258666 A1."},{"key":"e_1_2_11_141_1","unstructured":"IlligCR BallentineSK ChenJ DesjarlaisRL MeegallaSK WallM WilsonK.Imidazolecarboxamide compounds as inhibitors of c\u2010Fms kinase and their preparation pharmaceutical compositions and use in the treatment of diseases. US Pat Appl Publ 2007 US 20070249649 A1."},{"key":"e_1_2_11_142_1","unstructured":"IlligCR BallentineSK ChenJ DesjarlaisRL MeegallaSK WallM WilsonK.Imidazolecarboxamide compounds as inhibitors of c\u2010Fms kinase and their preparation pharmaceutical compositions and use in the treatment of diseases. US Pat Appl Publ 2007 US 20070249593 A1."},{"key":"e_1_2_11_143_1","unstructured":"IlligCR BallentineSK ChenJ DesjarlaisRL MeegallaSK WallM WilsonK.Imidazolecarboxamide compounds as inhibitors of c\u2010Fms kinase and their preparation pharmaceutical compositions and use in the treatment of diseases. US Pat Appl Publ 2007 20070249608 A1."},{"key":"e_1_2_11_144_1","unstructured":"MantheyCL.Preparation of imidazolecarboxamides and related compounds as c\u2010fms inhibitors for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer. WO 2009058801 A1 [PCT Int Appl 2009]."},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0255"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.04.059"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.09.057"},{"key":"e_1_2_11_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.05.013"},{"key":"e_1_2_11_149_1","unstructured":"IlligCR BallentineSK ChenJ MeegallaS RudolphJ WallMJ WilsonKJ DesjarlaisR MantheyCL FloresCM MolloyCJ.Preparation of aromatic amides as inhibitors of c\u2010fms kinase. WO 2006047504 A1 [PCT Int Appl 2006]."},{"key":"e_1_2_11_150_1","unstructured":"IlligCR BallentineSK ChenJ MeegallaSK RudolphMJ WallMJ WilsonKJ DesjarlaisRL MantheyCL FloresC MolloyCJ.Preparation ofN\u2010phenyl orN\u2010pyridyl heterocycliccarboxamides as inhibitors of c\u2010fms kinase. US 20060189623 A1 [US Pat Appl Publ 2006]."},{"key":"e_1_2_11_151_1","unstructured":"AlmeidaL AquilaB CookDon CowenS DakinL EzhuthachanJ IoannidisS LeeS LyneP PontzT ScottD SuM ZhengX.Preparation of pyridine carboxamides asCSF\u20101Rinhibitors for treating cancer. WO 2006067445 A2 [PCT Int Appl 2006]."},{"key":"e_1_2_11_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.04.088"},{"key":"e_1_2_11_153_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3967"},{"key":"e_1_2_11_154_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1711.2004.01296.x"},{"key":"e_1_2_11_155_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209007"},{"key":"e_1_2_11_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.09.007"},{"key":"e_1_2_11_157_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-104281"},{"key":"e_1_2_11_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2011.04.019"},{"key":"e_1_2_11_159_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1388"},{"key":"e_1_2_11_160_1","unstructured":"Letrozole (Femara) plus imatinib mesylate (Gleevec) for breast cancer patients.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00338728?term=imatinib&rank=22(Retrieved October 18 2011)."},{"key":"e_1_2_11_161_1","unstructured":"A study to investigate the safety and efficacy ofAT13387 alone or in combination with imatinib in patients withGIST.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01294202?term=imatinib&rank=53(Retrieved October 18 2011)."},{"key":"e_1_2_11_162_1","unstructured":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=imatinib(Retrieved October 18 2011)."},{"key":"e_1_2_11_163_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-5848fje"},{"key":"e_1_2_11_164_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.12.073"},{"key":"e_1_2_11_165_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio799"},{"key":"e_1_2_11_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(97)00035-8"},{"key":"e_1_2_11_167_1","unstructured":"MyersMR SpadaAP MaguireMP PersonsPE ZilbersteinA HsuC\u2010YJ JohnsonSE.Preparation of (hetero)arylquinazolines which inhibitCSF\u20101Rreceptor tyrosine kinase. US 5714493 A [US Pat 1998]."},{"key":"e_1_2_11_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.09.009"},{"key":"e_1_2_11_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.12.046"},{"key":"e_1_2_11_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.12.044"},{"key":"e_1_2_11_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.01.033"},{"key":"e_1_2_11_172_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0313"},{"key":"e_1_2_11_173_1","unstructured":"KuboK OhnoH IsoeT NishitobaT.Preparation of quinoline derivatives as inhibitors of autophosphorylation of macrophage colony stimulating factor receptor. WO 2003093238 [WO Pat Appl 2003]."},{"key":"e_1_2_11_174_1","unstructured":"KuboK OhnoH IsoeT NishitobaT.Preparation of quinoline derivatives as inhibitors of autophosphorylation of macrophage colony stimulating factor receptor. US 2006\/0235033 [US Pat Appl 2006]."},{"key":"e_1_2_11_175_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23903"},{"key":"e_1_2_11_176_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M413278200"},{"key":"e_1_2_11_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.01.088"},{"key":"e_1_2_11_178_1","unstructured":"SchewchukLM HassellAM HolmesWD VealJM EmmersonHK MussoDL ChamberlainSD PeckhamGE.Crystal structure of liganded cFMSkinase domain. US 2004\/0002145 [US Pat Appl 2004]."},{"key":"e_1_2_11_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2010.06.023"},{"key":"e_1_2_11_180_1","unstructured":"PlayerMR HuangH HuttaDA.5\u2010Oxo\u20105 8\u2010dihydro\u2010pyrido\u2010pyrimidines as inhibitors of c\u2010fms kinase. 0060577 A1 [WO Pat Appl 2007]."},{"key":"e_1_2_11_181_1","unstructured":"PlayerMR HuangH HuttaDA.5\u2010Oxo\u20105 8\u2010dihydro\u2010pyrido\u2010pyrimidines as inhibitors of c\u2010fms kinase. 0060578 A1 [WO Pat Appl 2007]."},{"key":"e_1_2_11_182_1","unstructured":"PlayerMR ParsonsWH HuangH HuttaDA HuH RinkerJ.5\u2010Oxo\u20105 8\u2010dihydropyridopyrimidines as inhibitors of c\u2010fms kinase and their preparation pharmaceutical compositions and use in the treatment of diseases. WO 2008055013 A2 [PCT Int Appl 2008]."},{"key":"e_1_2_11_183_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.02.070"},{"key":"e_1_2_11_184_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0333"},{"key":"e_1_2_11_185_1","unstructured":"AjamiAM BossMA PatersonJ.Treatment of autoimmune and demyelinating diseases withSymadex and related imidazoacridine derivatives. WO 2006081431 [PCT Int Appl 2006]."},{"key":"e_1_2_11_186_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0359"},{"key":"e_1_2_11_187_1","unstructured":"IbrahimPN ArtisDR BremerR HabetsG MamoS NespiM ZhangC ZhangJ ZhuY ZuckermanR WestB SuzukiY TsaiJ HirthK\u2010P BollagG SpevakW ChoH GilletteSJ WuG ZhuH ShiS.Pyrrolo[2 3\u2010b]pyridine derivatives as protein kinase inhibitors and their preparation pharmaceutical compositions and use in the treatment of diseases. WO 2007002433 [PCT Int Appl 2007]."},{"key":"e_1_2_11_188_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.127"},{"key":"e_1_2_11_189_1","unstructured":"MurrayL O'FarrellA\u2010M AbramsT.Preparation of indolinone compounds for treatment of excessive osteolysis. US 2004\/209937 [US Pat Appl 2004]."},{"key":"e_1_2_11_190_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28546."},{"key":"e_1_2_11_191_1","unstructured":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=sunitinib(Retrieved October 18 2011)."},{"key":"e_1_2_11_192_1","unstructured":"Neoadjuvant sunitinib with paclitaxel\/carboplatin in patients with triple\u2010negative breast cancer.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00887575?term=sunitinib&rank=2(Retrieved October 18 2011)."},{"key":"e_1_2_11_193_1","unstructured":"A phase II trial of sutent (sunitinib;SU011248) for recurrent anaplastic astrocytoma and glioblastoma.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00606008?term=sunitinib&rank=8(Retrieved October 18 2011)."},{"key":"e_1_2_11_194_1","unstructured":"A phase Ib study ofRad001 and sutent to treat renal cell carcinoma (Rad\/Sutent).http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00788060?term=sunitinib&rank=10(Retrieved October 18 2011)."},{"key":"e_1_2_11_195_1","unstructured":"Evaluation of patients with bulkyGISTusing sunitinib.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01054911?term=sunitinib&rank=12(Retrieved October 18 2011)."},{"key":"e_1_2_11_196_1","unstructured":"Thyroid cancer and sunitinib (THYSU).http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00510640?term=sunitinib&rank=40(Retrieved October 18 2011)."},{"key":"e_1_2_11_197_1","unstructured":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=ABT\u2010869(Retrieved October 18 2011)."},{"key":"e_1_2_11_198_1","unstructured":"Linifanib in treating patients with advanced refractory colorectal cancer.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01365910?term=Linifanib&rank=3(Retrieved October 18 2011)."},{"key":"e_1_2_11_199_1","unstructured":"An extension study of linifanib (ABT\u2010869) in subjects with advanced or metastatic solid tumors.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01413893?term=Linifanib&rank=7(Retrieved October 18 2011)."},{"key":"e_1_2_11_200_1","unstructured":"Efficacy and tolerability ofABT\u2010869 versus sorafenib in advanced hepatocellular carcinoma (HCC).http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01009593?term=Linifanib&rank=9(Retrieved October 18 2011)."},{"key":"e_1_2_11_201_1","unstructured":"Study of carboplatin\/paclitaxel in combination withABT\u2010869 in subjects with advanced or metastatic non\u2010small cell lung cancer (NSCLC).http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00716534?term=Linifanib&rank=10(Retrieved October 18 2011)."},{"key":"e_1_2_11_202_1","unstructured":"Pharmacodynamic study of axitinib in patients with advanced solid malignancies.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00859118?term=axitinib&rank=2(Retrieved October 18 2011)."},{"key":"e_1_2_11_203_1","unstructured":"Study ofAG\u2010013736 (axitinib) as second\u2010line treatment in patients with metastatic renal cell cancer (mRCC).http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00569946?term=axitinib&rank=19(Retrieved October 18 2011)."},{"key":"e_1_2_11_204_1","unstructured":"A study ofAG\u2010013736 (axitinib) or bevacizumab (avastin) in combination with paclitaxel and carboplatin in patients with advanced lung cancer.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00600821?term=axitinib&rank=9(Retrieved October 18 2011)."},{"key":"e_1_2_11_205_1","unstructured":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=axitinib(Retrieved October 18 2011)."},{"key":"e_1_2_11_206_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.5.741"},{"key":"e_1_2_11_207_1","unstructured":"SuttonJC WiesmannM WangW LindvallMK LanJ RamurthyS SharmaA MieuliEJ KlivanskyLM LenahanWP KaufmanS YangH NgSC PfisterK WagmanA SungV SendzikM.Preparation of 6\u2010O\u2010substituted benzoxazole and benzothiazole compounds for inhibitingCSF\u20101Rsignaling. WO 2007121484 A2 [PCT Int Appl 2007]."},{"key":"e_1_2_11_208_1","unstructured":"AbrahamS HolladayMW LiuG XuS.Preparation of biaryl compounds as modulators ofKIT CSF\u20101Rand\/orFLT3 kinase. WO 2011022473 A1 [PCT Int Appl 2011]."},{"key":"e_1_2_11_209_1","unstructured":"http:\/\/www.plexxikon.com\/view.cfm\/73\/press\u2010releases(Retrived October 18 2011)."},{"key":"e_1_2_11_210_1","unstructured":"http:\/\/www.saturday\u2010reviewdrugtrials.com\/content\/plexxikon\u2010announces\u2010data\u2010presentations\u2010oncology\u2010pipeline\u2010asco\u20102011(Retrived October 18 2011)."},{"key":"e_1_2_11_211_1","article-title":"Targeting brain tumors with PLX3397, an inhibitor of the CSF\u20101 receptor kinase","author":"West BL","journal-title":"Am Assoc Cancer Res (AACR)"},{"key":"e_1_2_11_212_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.05.1909"},{"key":"e_1_2_11_213_1","unstructured":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=plx3397(Retrived October 18 2011)."},{"key":"e_1_2_11_214_1","unstructured":"http:\/\/www.fiercebiotech.com\/press\u2010releases\/plexxikon\u2010initiates\u2010phase\u20102\u2010clinical\u2010trial\u2010hodgkin\u2010lymphoma\u2010plx3397\u20100?utm_medium=rss&utm_source=rss(Retrived October 18 2011)."}],"container-title":["Medicinal Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmed.21258","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmed.21258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.21258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T16:47:34Z","timestamp":1696351654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/med.21258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":213,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1002\/med.21258"],"URL":"https:\/\/doi.org\/10.1002\/med.21258","archive":["Portico"],"relation":{},"ISSN":["0198-6325","1098-1128"],"issn-type":[{"value":"0198-6325","type":"print"},{"value":"1098-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,20]]}}}